International Journal of Cancer · 2018 · 76 citations · 43 references
MedicineImmunologyOncologyInnate ImmunityMolecular OncologyTumor MicroenvironmentCancer BiomarkersMicrorna BiologyTumor Immune MicroenvironmentTumor Microenvironment InteractionsTumor Microenvironment ModulationTumor-associated MacrophagesCancer-associated MacrophagesCirculating MicrornasImmunosuppressive MicroenvironmentLung Cancer RiskMicrorna In CancerMicrorna ModulationMicrorna Regulation In CancerTumor-associated Neutrophils
miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.
43
Most mammalian mRNAs are conserved targets of microRNAs
Robin C. Friedman, Kyle Kai‐How Farh, Christopher B. Burge et al. · Genome Research · 2008 · 8.6K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Predicting effective microRNA target sites in mammalian mRNAs
Vikram Agarwal, George W. Bell, Jin‐Wu Nam et al. · eLife · 2015 · 7.7K citations · Full text
Guidelines for the welfare and use of animals in cancer research
Paul Workman, Eric O. Aboagye, Frances R. Balkwill et al. · British Journal of Cancer · 2010 · 1.4K citations · Full text
Medicine, Animal Sciences, Oncology +17
Distribution of miRNA expression across human tissues
Nicole Ludwig, Petra Leidinger, Kurt Becker et al. · Nucleic Acids Research · 2016 · 1K citations · Full text